BSE filing, NSE: SYMBIOTEC. Summary written from the filing by ALFA Finder's alert engine.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,246.30
- Market cap
- ₹8,008 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Share Pledge
Promoters of Symbiotec Pharmalab submitted a revised disclosure to update the lender and trustee names for their pledged share encumbrance.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31 of the SEBI LODR Regulations.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab has filed the routine quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending September 30, 2026.
Symbiotec Pharmalab Other Announcement
Designated persons of Symbiotec Pharmalab sold equity shares worth ₹11.94 crore in the open market. This disclosure complies with PIT Regulation 7(2).
- Value
- ₹11.94 Cr
Symbiotec Pharmalab Business Update
Symbiotec Pharmalab received an Establishment Inspection Report (EIR) from the U.S. FDA for its Pithampur manufacturing facility. The inspection concluded with a Voluntary Action Indicated (VAI) classification.
- From
- U.S. Food and Drug Administration (U.S. FDA)
Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways
Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.
- Call
- Guides 20% growth
Other board meeting date announcements
All →Oval Projects Engineering Board Meeting Date
Oval Projects Engineering will hold a board meeting on November 4, 2026 to consider half-year results and a warrant issue. Agenda items are proposed; no amount stated.
Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.
CHD Chemicals Board Meeting Date
CHD Chemicals intimated a board meeting on 04 Nov 2026 to consider unaudited half-yearly results for September 2026. Trading window remains closed until 06 Nov 2026.
Max Estates Board Meeting Date
Max Estates Limited has informed exchanges that its board will meet on 4 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 6 November 2026.
GKP Printing & Packaging Board Meeting Date
G.K.P. Printing & Packaging announced a board meeting on 4 November 2026 to approve unaudited results for the quarter ended 30 September 2026. Trading window has been closed for insiders since 1 October 2026.
ADF Foods Board Meeting Date
ADF Foods will hold a board meeting on November 5, 2026 to consider unaudited results for the quarter and half year ended September 30, 2026. The meeting will also consider an interim dividend for FY2026-27.